On-Demand CME Videos
The PA and NPs Role in Managing Atopic Dermatitis With Biologics in Clinical Practice: Online CME Activity
About
To learn the right answer to the following question, click "Start Activity"!
82-year-old female with a 4-month history of extremely pruritic papules and plaques with oozing and excoriations on trunk of body. Relevant past medical history of recurrent DVTs. The optimal treatment choice would be?
a. Topical steroids
b. Oral steroids
c. JAK Inhibitor
d. A biologic
e. Antibiotics with oral steroids
This activity was recorded at the 2023 Fall Clinical Dermatology Conference for PAs and NPs and is supported by an educational educational grants from LEO Pharma, Lilly, and Sanofi and Regeneron Pharmaceuticals, Inc.
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
July 18, 2023
July 18, 2024
Learning Objectives
At the completion of this activity, participants should be better able to:
Overview the role of biologics for the management of moderate-to-severe atopic dermatitis
Identify patients who would benefit from biologics for the management of moderate-to-severe atopic dermatitis
Discuss how PAs and NPs can work in a multidisciplinary team to manage patients with moderate-to-severe AD on biologics
Intended Audience
This activity has been designed for dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
Christopher Bunick, MD, PhD
Associate Professor of Dermatology
Yale University School of Medicine
New Haven, CT
Lauren Miller, MPAS, PA-C
Southern Skies Dermatology & Surgery
Oxford, AL
Gil Yosopovitch
Professor, Department of Dermatology and Cutaneous Surgery
Director, Miami Itch Center
University of Miami Miller School of Medicine
Miami, FL
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Grant/Research Support: Almirall
Consultant: Abbvie, BMS, Dermavant, EPI, Lilly, Mayne, Novartis, Sanofi Genzyme Regeneron
Speaker's Burea: Abbvie, BMS, Dermavant, Lilly, Sanofi Genzye Regeneron
Grant/Research Support: Eli Lilly, Escient, Galderma, Maruho, Pfizer, Sanofi Regeneron
Consultant: Abbvie, Arcutis,. Escient Health, Eli Lilly, Galderma, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals, Inc., Sanofi, Vifor
Speaker's Bureau: Maruho
Intellectual Property Rights: APAP cream
The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.